Dr. Colin Reisner is chief medical officer and EVP of Pearl Therapeutics, an AstraZeneca group company. He has over 20 years’ experience in the design of clinical studies in asthma, COPD and cystic fibrosis. Colin’s experience covers all aspects of drug development, ranging from early proof-of-concept studies to large Phase 3 programs for global registration and commercialization.
Dr. Colin Reisner is chief medical officer and EVP of Pearl Therapeutics, an AstraZeneca group company. He has over 20 years’ experience in the design of clinical studies in asthma, COPD and cystic fibrosis. Colin’s experience covers all aspects of drug development, ranging from early proof-of-concept studies to large Phase 3 programs for global registration and commercialization. Included among the products he has worked on are Combivent®, Serevent® Diskus®, Advair Diskus®, Xolair®and TOBI® Podhaler™
In 2007 Colin joined Pearl shortly after the Company’s incorporation and first financing. Here he designed the clinical development strategy and outsourcing model that allowed Pearl to advance its COPD LAMA/LABA combination product, PT003, through 10 clinical studies in four years. PT003 is currently being assessed in a global phase 3 program that has enrolled over 3,000 patients.
During his tenure at Pearl, Colin helped raise over $150 million, expanded the Company from five employees to more than 100, and was integrally involved in the discussions that preceded Pearl's acquisition by AstraZeneca.
Colin received his medical school training (MBBCH degree) from the University of Witwatersrand, Johannesburg, South Africa. He went on to receive specialist training in internal medicine at Danbury Hospital, a Yale affiliated program, followed by sub-specialty training in Allergy Immunology at National Jewish in Denver, CO. He previously held adjunct faculty positions at Yale and at Duke University. He is a fellow of the American College of Chest Physicians, a Fellow of the American Academy of Allergy Asthma and Immunology, is a member of the American Thoracic Society Drug/Device Discovery and Development sub-committee.
Specialties: Internal Medicine, Allergy and Immunology.
Design of clinical development programs to support global registration and commercialization of small molecules and biologics
Business development and licensing activities, scientific presentations
Head of Clinical, Respiratory Global Medicines, AstraZeneca @ From September 2014 to Present (1 year 4 months) Chief Medical Officer and Executive VP @ From October 2007 to Present (8 years 3 months) Executive Director, Respiratory Development @ Disease Area Section Head (2005-2007)
Brand Medical Director Xolair, (2003 – 2005) From 2003 to 2007 (4 years) Assistant Consulting Professor, Department of Medicine, Section of Allergy and Clinical Immunology @ From 2000 to 2003 (3 years) Senior Director, Respiratory Clinical Development and Medical Affairs @ From 1999 to 2003 (4 years) Assistant Clinical Professor, Department of Medicine,Section of Allergy and Clinical Immunology @ From 1996 to 1999 (3 years) Senior Associate Director, Pulmonary Division @ From 1995 to 1999 (4 years) Instructor in Medicine @ From 1991 to 1993 (2 years)
Fellowship in Allergy and Immunology, Allergy and Immunology @ National Jewish Medical and Research Center From 1993 to 1995 MBBCH, Medicine @ University of the Witwatersrand From 1982 to 1987 Colin Reisner is skilled in: Clinical Trials, Clinical Development, Immunology, Internal Medicine, Asthma, Drug Development, COPD, Cystic Fibrosis, Medical Affairs, GCP, Biotechnology, Translational Medicine, Hematology, Pharmaceutical Industry, Therapeutic Areas
Looking for a different
Get an email address for anyone on LinkedIn with the ContactOut Chrome extension